These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 10139375)

  • 21. Blinded review of papanicolaou smears.
    Frable WJ
    Cancer; 2004 Jun; 102(3):133-5. PubMed ID: 15211470
    [No Abstract]   [Full Text] [Related]  

  • 22. Papnet-assisted cytological diagnosis intensifies the already marked variability among cytological laboratories.
    Mudu P; Migliore G; Alderisio M; Morosini P; Douglas G; Navone R; Montanari G; Di Bonito L; Vitali A; Moretti D; Giovagnoli MR; Fulciniti F; Branca M;
    Eur J Gynaecol Oncol; 2002; 23(3):211-5. PubMed ID: 12094957
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [The cervico-vaginal smear. What is new with the Papanicolaou method in 1996?].
    Marsan C
    Bull Acad Natl Med; 1996 May; 180(5):1115-9; discussion 1120-4. PubMed ID: 8963710
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Liability issues with the Papanicolaou smear: the view of a hospital administrator at Newport Hospital, Newport, Rhode Island.
    Sampson AJ
    Arch Pathol Lab Med; 1997 Mar; 121(3):241-5. PubMed ID: 9111108
    [No Abstract]   [Full Text] [Related]  

  • 25. Rapid prescreening of Papanicolaou smears: a practical and efficient quality control strategy.
    Djemli A; Khetani K; Auger M
    Cancer; 2006 Feb; 108(1):21-6. PubMed ID: 16302251
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Improving Papanicolaou test quality and reducing medical errors by using Toyota production system methods.
    Raab SS; Andrew-Jaja C; Condel JL; Dabbs DJ
    Am J Obstet Gynecol; 2006 Jan; 194(1):57-64. PubMed ID: 16389010
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Preliminary study concerning the cytoscreen system importance (liquid based cytology) in gynecologic cytology.
    Popescu CF; Bădulescu A; Bădulescu F; Cotarcea S; Găvănescu M
    Rom J Morphol Embryol; 2005; 46(1):23-7. PubMed ID: 16286981
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The false-negative fraction for Papanicolaou smears: how often are "abnormal" smears not detected by a "standard" screening cytologist?
    Naryshkin S
    Arch Pathol Lab Med; 1997 Mar; 121(3):270-2. PubMed ID: 9111116
    [TBL] [Abstract][Full Text] [Related]  

  • 29. One hundred percent thorough quality control rescreening of liquid-based monolayers in cervicovaginal cytopathology.
    Rowe LR; Marshall CJ; Bentz JS
    Cancer; 2002 Dec; 96(6):325-9. PubMed ID: 12478679
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Malpractice protection: communication of diagnostic uncertainty.
    Skoumal SM; Florell SR; Bydalek MK; Hunter WJ
    Diagn Cytopathol; 1996 Jun; 14(4):385-9. PubMed ID: 8725143
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Papanicolaou smear sensitivity for the detection of adenocarcinoma of the cervix: a study of 49 cases.
    Krane JF; Granter SR; Trask CE; Hogan CL; Lee KR
    Cancer; 2001 Feb; 93(1):8-15. PubMed ID: 11241260
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Rapid pre-screening of cervical smears as a method of internal quality control in a cervical screening programme.
    Tavares SB; de Sousa NL; Manrique EJ; de Albuquerque ZB; Zeferino LC; Amaral RG
    Cytopathology; 2008 Aug; 19(4):254-9. PubMed ID: 18476988
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Weekly rescreening of 10% of the total cervical Papanicolaou smears: a worthwhile quality assurance scheme.
    Sampatanukul P; Wannakrairot P; Promprakob U; Yodavudh S; Anansiriprapa C
    J Med Assoc Thai; 2004 Sep; 87 Suppl 2():S261-5. PubMed ID: 16083199
    [TBL] [Abstract][Full Text] [Related]  

  • 34. PAPNET-assisted primary screening of conventional cervical smears.
    Cenci M; Nagar C; Vecchione A
    Anticancer Res; 2000; 20(5C):3887-9. PubMed ID: 11268471
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [An interlaboratory study of the use of PapNet in the quality control of cervico-vaginal cytology].
    Cosentino A; Ghidoni D; Salemi M; Folicaldi S; Amadori A; Zani J; Grasso G; Bondi A
    Pathologica; 1999 Apr; 91(2):101-6. PubMed ID: 10484869
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Value of a computer-assisted screening method (PAPNET) for the detection of infectious cervico-uterine smears].
    Bernier M; Bergemer AM; Got C; Marsan C
    Arch Anat Cytol Pathol; 1998; 46(3):184-7. PubMed ID: 9754374
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Partial re-screening of all negative smears. A method of quality control of pathology department concerning smear screening against cervix cancer].
    Jensen ML; Dybdahl H; Svanholm H
    Ugeskr Laeger; 2000 May; 162(21):3024-7. PubMed ID: 10850190
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [False negative Pap smears in a Danish material].
    Ejersbo D; Dahl MB; Hølund B
    Ugeskr Laeger; 2003 Jun; 165(23):2391-4. PubMed ID: 12840998
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Quality control of cervical cytology in high-risk women. PAPNET system compared with manual rescreening.
    Bergeron C; Masseroli M; Ghezi A; Lemarie A; Mango L; Koss LG
    Acta Cytol; 2000; 44(2):151-7. PubMed ID: 10740599
    [TBL] [Abstract][Full Text] [Related]  

  • 40. New tests for cervical cancer screening.
    Nuovo J; Melnikow J; Howell LP
    Am Fam Physician; 2001 Sep; 64(5):780-6. PubMed ID: 11563569
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.